Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226158 · ClinicalTrials.gov registry record
Next Generation Pathogen Sequencing for Prediction of Adverse Events
A clinical trial of Bloodstream Infection, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT03226158 is a study of Bloodstream Infection that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 160 participants, above the 35-participant average among 3 other Bloodstream Infection trials with a reported enrollment target (357% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03226158, a study of Bloodstream Infection, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The majority of children and adolescents diagnosed with cancer will experience one or more episodes of fever or infection during their course of therapy. The most common microbiologically documented infection is bloodstream infection (BSI), which can be associated with severe sepsis or death. Current methods of diagnosis require a significant load of live bacteria in the blood making early detection difficult. Delayed diagnosis and delayed optimal therapy of BSIs are associated with increased morbidity and mortality. This study seeks to identify whether next generation sequencing (NGS) of pathogens can identify patients with impending bloodstream infection. This would enable preemptive targeted therapy to replace antibacterial prophylaxis which often leads ot high-density broad-spectrum antibiotic exposure and contributes to subsequent development of antibiotic resistance. PRIMARY OBJECTIVE: * To estimate the sensitivity and specificity of next generation pathogen sequencing for prediction of bloodstream infection in children with cancer at high risk of infection.
Conditions Studied
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2017-08-09 |
| Est. Completion | 2026-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226158
The ClinicalTrials.gov registry entry for NCT03226158 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 3 other Bloodstream Infection trials with a reported enrollment target (357% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bloodstream Infection appearing as the primary indexed condition, and to 0 interventions.
NCT03226158 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT03226158 about?
NCT03226158 is a clinical study titled "Next Generation Pathogen Sequencing for Prediction of Adverse Events". The majority of children and adolescents diagnosed with cancer will experience one or more episodes of fever or infection during their course of therapy. The most common microbiologically documented infection is bloodstream infection (BSI), which can be associated with severe sepsis or death. Curren...
What is the current status of trial NCT03226158?
This trial is currently active not recruiting. The enrollment target is 160 participants. The study started on 2017-08-09. Estimated completion is 2026-03-01.
What conditions does trial NCT03226158 study?
This clinical trial studies the following conditions: Bloodstream Infection.
Who is sponsoring clinical trial NCT03226158?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03226158 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bloodstream Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)
RECRUITING · NA
-
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
COMPLETED · Phase 1
-
Catheter Related - Gram Positive Bloodstream Infections
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.